The orally administered anti-allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000032:analysis*; D004804:Eosinophils / Q000187:drug effects*; D005260:Female; D006633:Histamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis*; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008448:Maximal Expiratory Flow Rate
D006633:Histamine Antagonists; D007189:Indans; D007192:Indenes; C012136:nivimedone; D007073:Immunoglobulin E; D003165:Complement System Proteins